Novel Personalized Cancer Vaccine Using Tumor Extracellular Vesicles with Attenuated Tumorigenicity and Enhanced Immunogenicity.

Adv Sci (Weinh) · 2024 · PMC11220679 · PMID 38666427

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

BMDCs cultured with E.G7‐OVA‐derived TEVs were analyzed for cross‐presentation of OVA (SIINFEKL) peptide and showed a highly significant enhancement of DC cross‐presentation in groups treated with AI‐TEVs (Figure 3G ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.